• If you are wondering whether CME Group's current share price really reflects its underlying worth, this breakdown will help you frame that question clearly before you make any decisions.
• The stock recently closed at US$308.90, with returns of 1.8% over 7 days, 1.9% over 30 days, 14.5% year to date and 20.8% over the past year. This naturally raises questions about how much of the story is already priced in.
• Recent news coverage has focused on CME Group's role as a major exchange operator and how that position fits into shifts in trading activity and investor sentiment. This backdrop is important context for assessing whether recent price moves align with fundamentals or are more sentiment driven.
• Right now CME Group has a valuation score of 1 out of 6. The next sections will look at how different valuation methods assess the stock, and then finish with a way of thinking about valuation that can be even more useful than any single metric.

CME Group scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: CME Group Excess Returns Analysis

The Excess Returns model looks at how much value CME Group creates over and above the required return that shareholders expect. Instead of focusing on cash flows, it starts with the equity on the balance sheet and asks how efficiently that equity is being used.

For CME Group, the model uses a Book Value of $80.03 per share and a Stable EPS of $13.80 per share, based on weighted future Return on Equity estimates from 5 analysts. The Average Return on Equity is 15.61%, while the Cost of Equity is $6.94 per share. The gap between what the equity is expected to earn and what investors require is the Excess Return, estimated at $6.86 per share.

The analysis also assumes a Stable Book Value of $88.43 per share, sourced from weighted future Book Value estimates from 3 analysts. These inputs are combined to arrive at an intrinsic value of about $243.10 per share. Compared with the recent share price of $308.90, the model suggests the stock is around 27.1% overvalued.

Result: OVERVALUED

Our Excess Returns analysis suggests CME Group may be overvalued by 27.1%. Discover 49 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: CME Group Price vs Earnings

For a profitable company like CME Group, the P/E ratio is a useful way to link what you are paying per share to the earnings that each share generates. It gives a quick sense of how much the market is willing to pay for current earnings.

What counts as a “normal” P/E often reflects how the market views a company’s growth prospects and risk profile. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually justify a lower one.

CME Group is currently trading on a P/E of 27.55x. That sits close to both the Capital Markets industry average P/E of 26.92x and the peer average of 28.59x. This suggests the market is broadly in line with how similar businesses are priced. Simply Wall St’s Fair Ratio for CME Group is 15.57x. This is the P/E that would typically be expected given factors like its earnings characteristics, industry, profit margins, market cap and risk profile.

This Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for the company’s own fundamentals rather than assuming that all peers deserve similar multiples. Comparing 27.55x to the Fair Ratio of 15.57x points to CME Group trading above what this framework would consider a fair P/E.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your CME Group Narrative

Earlier it was mentioned that there is an even better way to think about valuation, so Narratives are introduced here as a simple way for you to connect your view of CME Group’s story with concrete numbers such as your own fair value, revenue, earnings and margin assumptions. You can then compare that fair value to today’s price to decide whether you see the stock as attractive or not.

Do you think there's more to the story for CME Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.